A 25-year-old female visited her primary care physician complaining about weight gain over the past 2 and a half months. She has not had any changes with diet or exercise, yet she has gained 10 pounds. She also has had chronic fatigue over this period and has recurring constipation. Her skin appears pale and she mentions feeling extreme cold sensitivity, even when the temperature of a room feels fine to others.
It has been suggested that the human body has an intrinsic weight sensor that functions as part of energy homeostasis. Information about body weight is used to drive caloric intake and metabolic expenditure with the goal of maintaining body weight at a specific set point, however little is known about how such a sensor might function. In a recent paper, published in the journal EClinicalMedicine researchers from the University of Gothenburg, Sweden, have devised a method to investigate this system they have dubbed the “graviostat,” using weighted vests.
The findings can lead to new interventions to prevent the development of diabetes in older men.
New research suggests severe sleep apnea was linked to increased blood glucose levels in African-Americans.
ABG-023 overcomes the limitations glucagon because it remains stable in solutions.
Obesity-related conditions seem to worsen the effect of COVID-19. The Centers for Disease Control and Prevention (CDC) reported that people with heart disease and diabetes are at higher risk of COVID-19 complications, and the World Obesity Organization predicts that a large percentage of patiients with the coronavirus will have a BMI over 25. Many aspects of patient management can be more difficult in the obese patient, including diagnostic imaging, intubation, positioning, and transport, making it more important than ever for patients and their physicians to prioritize weight management strategies.
Overweight, hypertensive patients who enrolled in a self-administered, internet-based health management program had better outcomes than patients who did not join the program, according to recent study findings.
In an effort to settle the debate surrounding the use of ACE inhibitors (ACEI) and ARBs during the ongoing coronavirus disease 2019 (COVID-19) outbreak, investigators from Perelman School of Medicine at the University of Pennsylvania, recently launched a new clinical trial. The REPLACE COVID trial plans to recruit 152 hospitalized patients already taking medications from the classes, with the goal of determining whether discontinuing use affects the severity of disease symptoms.
Bhatt leads discussion on a new AHA statement regarding one of the most advancing fields of cardiovascular care.
Patients with TED might be particularly vulnerable to COVID-19 infections.
A discussion about a recent scientific statement outlining the treatment of coronary artery disease in type 2 diabetics from the AHA with statement co-author Deepak Bhatt, MD.
Investigators compare cesarean delivery to vaginal delivery to understand the association between delivery type and obesity and type 2 diabetes.
Investigators from Saint Louis University discuss a new comparison of 2 drug classes that could reduce the risk of adverse cardiovascular events.
A new scientific statement from the AHA offers guidance to clinicians tasked with treating CAD in patients with type 2 diabetes.
Results of a new study dive deeper into the impact of preoperative metformin use in diabetics.
Endocrinologists make can a difference in COVID-19 by restricting their use of glucocorticoids. According to an editorial published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism, patients treated with glucocorticoids will be at higher risk for coronavirus disease 2019 (COVID-19), the infection caused by the novel coronavirus.
Patrick Campbell sat down with Paul Stewart, MD, Executive Dean of the Faculty of Medicine and Health at University of Leeds and editor in chief of the Journal of Clinical Endocrinology & Metabolism to discuss why endocrinologists are expressing additional concern for their patients during the COVID-19 outbreak.
Discussing the impact of the ongoing outbreak on endocrinology practices and endocrinologists with the Executive Dean of the Faculty of Medicine and Health at University of Leeds.
Discussing an editorial in the Journal of Clinical Endocrinology & Metabolism with journal editor in chief Paul Stewart, MD.
A new perspective from federal and institutional experts explains the cause of disease severity and mortality in older, cardiovascular-risk patients.
A new perspective from a team of Maryland-based cardiovascular clinicians sheds insight on an often forgotten facet of the inherent COVID-19 risk carried by patients with cardiovascular history: the decline in angiotensin-converting enzyme 2 (ACE2) expression associated with aging, and the response of care most common in such patients.
There is a growing understanding that obesity and non-alcoholic fatty liver disease are related.
Currently, guidelines call for liver biopsies to diagnose NASH disease in patients.
Bout moderate-to-vigorous physical activity does not increase as much in very poor fitness groups.
The findings can lead to more education on the risk of thyroid immune-related adverse event.
